Announcement PDF OCTOBER 20th, 2025 NASDAQ: RADX / ASX: RAD CLINICAL UPDATE AND CAPITAL RAISING Notice & Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward- looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law. This presentation is not a prospectus or other disclosure document under the Corporations Act 2001 (Cth) and will not be lodged with the Australian Securities and Investments Commission. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this presentation, you should observe such restrictions as any non- compliance with these restrictions could contravene applicable securities laws (see the section captioned ‘International offer restrictions’). In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change. 2 PROGRAM TARGET & MOLECULE INDICATION ISOTOPE PRECLINICAL PHASE I PHASE 2A PHASE 2B NOTES RAD101 Short Chain Fatty Acid (small molecule) Brain Mets F18 Phase 2b enrolling, NCT06777433 12 patients dosed / 30 patients total Expect to complete enrollment 1Q26 RAD202 HER2 (nanobody) HER2+ solid tumors Lu177 Phase 1 enrolling, NCT06824155 DL 1 at 30mCi completed DL 2 at 75mCi recruiting RAD204 PD-L1 (nanobody) PD-L1+ solid tumors Lu177 Phase 1 enrolling, NCT06305962 DL1 at 30mCi completed DL2 at 60mCi completed DL3 at xxmCi (DSMC decision in mid November) RAD301 Integrin [avB6] (peptide) Integrin αvβ6+ Pancreatic cancer Ga68 Phase 1 imaging trial enrolling, NCT05799274 6 patients dosed / 9 patients total Clinical Data Update From Four Clinical Trials (Oct 20th, 2025) 3 Molecule: 18F-RAD101 Targeting MoA: SHORT CHAIN FATTY ACIDS Imaging for: SUSPECTED RECURRENT BRAIN METASTASES 4 RAD 101 (PIVALATE) SMALL MOLECULE Selectively targets fatty acid synthase: overexpressed in tumors but not normal brain cells Imaging for Brain Metastasis CANCER CELL TARGET Fatty acid oxidation TARGETING MOLECULE pivalate LINKER RADIOACTIVE ISOTOPE 18F FATTY ACID SYNTHASE IS A VIABLE TARGET ✚ Upregulation of de novo fatty acid synthesis via Fatty Acid Synthase (FASN) enables cancer cells to grow in lipid-deprived brain microenvironment. ✚ Disruption of FASN activity can impair growth of brain metastases, representing a viable therapeutic target. IMAGING ✚ First-in-class Phase 2b imaging study currently recruiting (US).* ✚ High unmet need to detect early relapse after Stereotactic Radio Surgery in brain metastases from solid tumors of different origin ✚ ~300,000 new subjects diagnosed every year (US only) RAD 101 DIAGNOSTIC *NCT06777433 18F, fluorine-18; IIb, phase 2b; PET, positron emission tomography; US, United States. 5 Phase 2b Trial Design Phase 2b imaging study in participants with suspected recurrent brain metastases from solid tumors IV, intravenous; MBq, megabecquerel; mCi, millicurie; MRI, magnetic resonance imaging; PET, positron emission tomography; SRS, stereotactic radiosurgery. 6 • Study Design: Single dose RAD101, max 370 MBq (10 mCi), administered IV followed by whole brain PET/MRI scan at 60 ± 10 min post-dose. Four-week screening period, 3-day imaging and safety follow-up, longitudinal imaging and data collection up to 6 months. Study size: n=30. RAD 101 DIAGNOSTIC Eligibility • Known history of brain metastases (lung, breast, colon, kidney, melanoma) • Suspected relapse or progression following stereotactic radiosurgery (SRS) 10mCi RAD101 Whole Brain PET (N=30) Endpoints • Concordance between PET and MRI lesions 6 Months Longitudinal Follow-up ▪ Phase 2b imaging study currently recruiting (USA)* ▪ No competitor identified; RAD 101 is the only PET agent in clinical development for Brain Mets ▪ Large total addressable market: 300,000 new subjects diagnosed every year (US only) RAD 101 DIAGNOSTIC: CLINICAL DEVELOPMENT * NCT06777433 PRECLINICAL PHASE I PHASE 2a PHASE 2b PHASE 3 UK UK 24 pts 22 pts 30 pts 150 pts 7 US UK UK UK • RAD Phase 2b Study is currently ongoing and recruiting subjects • Images from n=3 subjects in the ongoing study demonstrate the concept by showing increased metabolic activity in areas with equivocal MRI findings (suspected relapse) • N=12 subjects dosed as of 10/20/2025; expected n=20 subjects by December; N=30/30 pts by Feb 2026 • Phase 2b readout in the first half of 2026 Executive Summary - new clinical data RAD 101 DIAGNOSTIC 1S. Islam et. Al., EJNMMI; 07 February 2025; https://doi.org/10.1007/s00259-025-07118-0 MRI, magnetic resonance imaging; SOC, standard of care; SUV, standardized uptake value. 8 Study Patient #1 Note: the PET of patient #1 and patient #2 have inverted gray scales. In patient #1, PET metabolic activity is black. In patient #2, activity is white MRI, magnetic resonance imaging; PET, positron emission tomography; SRS, stereotactic radiosurgery. 9 RAD 101 DIAGNOSTIC MRI shows a suspected relapsed brain metastasis after SRS (see reticle) PET shows dark spot of metabolic activity in same location, increasing the possibility of this being a relapse MRI PET Study Patient #2 Note: the PET of patient #1 and patient #2 have inverted gray scales. In patient #1, PET metabolic activity is black. In patient #2, activity is white MRI, magnetic resonance imaging; PET, positron emission tomography; SRS, stereotactic radiosurgery. 10 RAD 101 DIAGNOSTIC MRI shows a suspected relapsed brain metastasis after SRS (see reticle). It is unclear if this is active tumor or necrosis following SRS (appearance of a cavity) MRI PET PET shows high metabolic activity (white ring) surrounding a dark necrotic area (cavity) which is strongly indicative of a relapsed brain metastasis surrounding a necrotic area Study Patient #3 MRI with suspected relapsed brain metastasis after SRS. It is unclear if this (or how much) is active tumor or necrosis following SRS PET scans showing high metabolic activity in a significantly larger area of the brain compared to the MRI, indicative of a relapsed brain metastasis beyond the area in question from MRI MRI PET PET 11 RAD101 COMMERCIAL POTENTIAL: USD$500m+ yearly sales ( U S A o n l y ) T h i r d l a r g e s t i m a g i n g m o l e c u l e a f t e r P i l a r i f y ( L a n t h e u s ) & I l l u c i x ( T e l i x ) 12 RAD101 Estimated Sales Based on a number of assumptions outlined below, RAD 101 market share is projected to peak at 94.2% in Year 8 of commercialisation, generating revenue in excess of USD$500m Note: 1 In the scenario where RAD101 is the sole product on the market, the peak market share of 100% has been adjusted with a 5% discount factor to account for potential deviations in HCP behavior, such as non-adherence to guidelines or shifts in the SoC. Source: Definitive Healthcare; Primary research: Alira Health analysis Key Assumptions • Target population: Post SRS Treatment PET + MRI • Competition: None - RAD 101 is the only PET agent in clinical development for Brain Mets • Number of post-therapy (SRS) scans: 1.1 • ASP per dose: USD$3,917 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 1 to Year 8 Molecule: 177Lu-RAD202 Targeting MoA: HER2 Therapeutic for: HER2+ TUMORS 13 RAD 202 Utilizes Anti-PD-L1 Nanobody as Targeting Moiety CANCER CELL TARGET HER2 TARGETING MOLECULE Sd mAb LINKER RADIOACTIVE ISOTOPE 177Lu HER2+ THERAPY FOR subjects REFRACTORY TO TRASTUZUMAB DERUXTECAN (Enhertu®) Post-Enhertu® Market Increasingly Attractive ✚ Enhertu® moving up treatment lines (DESTINY-BREAST trials) ✚ Eligible patient numbers increasing (HER2-low/very low identification and approval) ✚ No established therapy following Enhertu® (total addressable market ~ USD 8-9 $B) HER2 NANOBODY High specificity & affinity single-domain antibody • HER2 pathway well validated • Overexpression in breast, and gastroesophageal cancers • Improved tumor penetration, accumulation and rapid blood clearance (small size) RAD 202 THERAPEUTIC HER2, human epidermal growth factor receptor 2; kDa, kilodalton; mAb, monoclonal antibody; nm, nanometer; Sd, single domain; USD, United States dollar. 14 Primary Objectives (Phase 1, Treatment): o Safety and tolerability of 177Lu-RAD202 o Recommended ph2 dose of 177Lu-RAD202 Population: Her2+ (IHC, ISH) a/m solid tumors Phase 0 Imaging: Biodistribution, PK and radiation dosimetry of 177Lu-RAD202im in organs of interest and tumor lesions Phase I Therapeutic: 177Lu-RAD202tr dose escalation Phase 1 Trial Design ‘HEAT’ Trial (HER2 Antibody Therapy with Lutetium-177) in subjects with HER2+ advanced solid tumors a/m, advanced or metastatic; DL, dose level; GBq, gigabecquerel; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; Lu177, lutetium-177; mCi, millicurie; PK, pharmacokinetics; TBD, to be determined. 15 RAD 202 THERAPEUTIC Dose Level Dose Phase 0 (Imaging Period with 177Lu- RAD202im) Imaging dose 10 mCi Phase I (Treatment Period with 177Lu- RAD202tr) Therapeutic DL1 30 mCi (1.1 GBq) DL2 75 mCi (2.7 GBq) DL3+ TBD PROGRAM TARGET & MOLECULE INDICATION Dx/Tx ISOTOPE 1ST HALF 2024 2ND HALF 2024 1ST HALF 2025 2ND HALF 2025 1ST HALF 2026 2ND HALF 2026 RAD 202 HER2 (Nanobody) HER2+ Solid Tumors Therapy Lu177 Preclinical Studies Completed Ethics Approval (Dec 2024) First Patient dosed 2 Cohorts Completed 2 Cohorts Data Release Phase 1 Last Patient Dosed • There are currently n=3 subjects in treatment in cohort #1 (30 mCi) with data available • DSMC on Sept 30th, approved the start of Cohort #2 at 75mCi • Significant amount of drug uptake (absorbed radiation dose) is observed in tumor lesions (cohort #1) • The safety profile has been very favorable, with few low-grade adverse events and no SAEs observed thus far Executive Summary | Current Study Status 1Zhao et al, Br Canc Res (2024); Zhao et al, Mol Pharmaceut (2021) 99mTc, technetium-99m; 177Lu, lutetium-177; mCi, millicurie; NSCLC, non-small cell lung cancer; PD-1, programmed death-1; PD-L1, programmed death ligand-1; PFS, progression-free survival. 16 RAD 202 THERAPEUTIC Lesion Dosimetry | First 3 Patients Show Very High Tumor Uptake PATIENT #1 Absorbed Dose at 30 mCi Cycle Lesion Volume (ml)2 Dose (Gy), with PVC1,2 C1 ROI-2 2.26025 3.57 C1 ROI-3 3.634 2.07 C1 ROI-4 10.36125 2.02 C1 ROI-5 16.20966667 0.39 1Partial Volume Correction applied. 2Density of lesion: soft tissue = 1.0 g/mL. Bone = 1.3 g/mL 3Lesions were contours based on thresholding (40%) method and volume was averaged over all timepoints *BR = background – shoulder and proximal thigh. T:BR = lesion SUVmax:BR SUVmean GBq, gigabecquerel; Gy, gray; ml, milliliter; PVC, partial volume correction; ROI, region of interest; SUV, standardized uptake value; SUVmax, maximum standardized uptake value; SUVmean, mean standardized uptake value; TBR, target-to-background ratio. 17 RAD 202 THERAPEUTIC NM1 – SEC 2 5TP Baseline PET D0 ACSCRR [BQML 9.85] NM2a – SEC 3 5TP 2nd follow up PET C1D2 ACSCRR [BQML 9.85] NM4 – SEC 5 Current PET C1D8 ACSCRR [BQML 9.85] SUV 6 5 4 3 2 1 0 7 Absorbed Dose at 30 mCi Cycle Lesion Volume (ml) Dose (Gy), with PVC1,2 C1 ROI-3 5.821 2.732 C1 ROI-6 23.02025 1.581 C1 ROI-7 43.224 1.831 C1 ROI-8 145.1585 1.286 C1 ROI-9 16.796 2.084 C1 ROI-10 20.9355 2.092 C1 ROI-11 20.31075 2.959 C1 ROI-12 20.31075 1.558 C1 ROI-13 30.34125 0.854 PATIENT #2 Absorbed Dose at 30 mCi Cycle Lesion (refer to Viedoc for lesion’s location for each ROI) Volume (ml) Dose (Gy), with PVC1,2 C1 ROI-2 48.7975 0.848 C1 ROI-3 60.502 0.661 C1 ROI-4 25.8 0.793 C1 ROI-6 26.85 0.964 C1 ROI-11 17.256 1.235 PATIENT #3 Treatment Emergent and Treatment-Related Adverse Events • All TEAEs in Dose Levels 1 were CTC Grade 1 and 2 • Only two AEs (both in the same patient) were considered ‘related’ by the treating physician: Grade 1 dysgeusia and Grade 1 pleural effusion Serious Adverse Events • There were no SAEs reported in Dose Level 1 Adverse Events Summary (interim data) | Dose Level 1 Molecule: 177Lu-RAD204 Targeting MoA: PD-L1 Therapeutic for: PD-L1+ TUMORS 19 RAD 204 Utilizes Anti-PD-L1 Nanobody as Targeting Moiety RAD 204 THERAPEUTIC CANCER CELL TARGET PD-L1 TARGETING MOLECULE Sd mAb LINKER RADIOACTIVE ISOTOPE 177Lu BENEFITS OF NANOBODIES ✚ Specificity and affinity of a full-size antibody; binds to different epitopes than approved full-sized antibodies ✚ Improved tumor penetration and accumulation (small size) ✚ Rapid blood clearance Anti-PD-L1 Nanobody High affinity single domain monoclonal antibody PD-L1 Immune Checkpoint • Antigen expression mediates evasion of immune responses by cancer cells • Inhibition leads to antitumor activity THERAPEUTIC APPLICATION ✚ First-in-class PD-L1 radiotherapeutic in development ✚ High unmet need in subjects refractory to Checkpoint Inhibitors ✚ Very large total addressable market in 2nd line metastatic, post Checkpoint Inhibitors+ chemotherapy 20 Dose Level Dose Phase 0 (Imaging Period with 177Lu-RAD204im) Imaging dose 10 (0.37 GBq) Phase I (Treatment Period with 177Lu-RAD204tr) Therapeutic DL1 30 mCi (1.1. GBq) DL2 60 mCi (2.2 GBq) DL3+ TBD Phase 1 Trial Design 177Lu-anti-PD-L1 single domain AB in metastatic solid tumors 21 Primary Objectives o Safety and tolerability of 177Lu-RAD204 o Recommended ph2 dose of 177Lu-RAD204tr Study Design BOIN for escalation / de-escalation. Population: History of PD-L1 positive (>1%) metastatic tumors Imaging Phase 0 Biodistribution, dosimetry and PK with low dose 177Lu-RAD204im in organs of interest and tumor Therapeutic Phase 1 177Lu-RAD204tr dose escalation RAD 204 THERAPEUTIC BOIN, Bayesian optimal interval; DL, dose level; GBq, gigabecquerel; mCi, millicurie; PD-L1, programmed death ligand-1; PK, pharmacokinetics; TBD, to be determined. PROGRAM TARGET & MOLECULE INDICATION Dx/Tx ISOTOPE 1ST HALF 2024 2ND HALF 2024 1ST HALF 2025 2ND HALF 2025 1ST HALF 2026 RAD 204 NCT06305962 PD-L1 (Nanobody) PD-L1+ Solid Tumors Therapy Lu177 Ethics Approval Received • First Patient Treated • Approval for Trial Expansion in 6 Tumor Types 1 Cohort Completed 2 Cohorts Completed Phase 1 dose escalation completed Executive Summary – Current Study status *One patient (Patient 003-009) is not DLT-evaluable (consent withdrawal due to personal reasons) NSCLC, non-small cell lung cancer; PD-1, programmed death-1; PDL-1, programmed death ligand-1; PFS, progression-free survival. • Preliminary data are available from n=3 subjects in cohort #1 (30mCi) and n=3* subjects from cohort #2 (60mCi) • DSMC meeting planned for mid of November to certify Cohort #2 completion and to approve start of Cohort #3 • The clinical activity is under evaluation. Thus far, 2/3 subjects (67%) at the lowest (30mCi) dose level have shown disease stabilization and treatment duration of 5+ months, which exceeds the typical PFS of approximately 3.5 months reported in such a last line patient population of NSCLC • The safety profile has been very favorable, with few adverse events and no related SAEs observed thus far RAD 204 THERAPEUTIC 22 RAD 204 THERAPEUTIC Absorbed dose at 30 mCi Cycle Lesion Volume (ml)2 D1 SUVmax SUV T:BR* Dose (Gy), with PVC1,2 C1 Primary (left lung apex) 111.87583 2.8 4.36 0.18 C1 Primary - core 11.48 0.46 C1 RLL met 32.35063 2.95 4.57 0.23 C1 RLL met - CT 5.974 0.59 C1 RML met 25.61963 4.2 6.09 0.52 C1 RML met – core 11.44 0.78 1Partial Volume Correction applied. 2Density of lesion: soft tissue = 1.0 g/mL. Bone = 1.3 g/mL 3Lesions were contours based on thresholding (40%) method and volume was averaged over all timepoints 4CT-based contouring is smaller than 11.5 mL. So the “core” contouring was not performed. *BR = background – shoulder and proximal thigh. T:BR = lesion SUVmax:BR SUVmean 23 SUV 6 5 4 3 2 1 0 7 C1 RML C1 RLL Location of sampling PD-L1 expression IHC (%) Right lung 10 Lesion Dosimetry | 003-001 (NSCLC) Selective uptake of 177Lu-RAD204 in primary and metastatic pulmonary lesions Lesion Dosimetry | 003-002 (sqNSCLC) Selective uptake of 177Lu-RAD204 in pulmonary lesions RAD 204 THERAPEUTIC Absorbed dose at 30 mCi Cycle Lesion Volume (ml)2 D1 SUVmax SUV T:BR* Dose (Gy), with PVC1 C1 Primary (Left lung perihilar) 151.42864 4.54 6.16 0.16 C1 Primary – core 11.47 0.74 C23 Primary 201.224 0.15 C23 Primary - core 11.288 0.77 1Partial Volume Correction applied 2Density of lesion: soft tissue = 1.0 g/mL. Bone = 1.3 g/mL 3C2 dosimetry is based on STD approach. 4Lesions were contours based on thresholding (40%) method and volume was averaged over all timepoints. *BR = background – shoulder and proximal thigh. T:BR = lesion SUVmax:BR SUVmean 24 SUV 6 5 4 3 2 1 0 7 C2D1 C1D1 C3 C1D2 C4 C1D3 Location of sampling PD-L1 expression IHC (%) Left lung 95 Lesion Dosimetry | 003-006 (NSCLC) Selective uptake of 177Lu-RAD204 in primary and metastatic pulmonary lesions RAD 204 THERAPEUTIC Absorbed dose at 30 mCi Cycle Lesion Volume (ml)2 D1 SUVmax SUV T:BR* Dose (Gy), with PVC1 Im Primary (RUL) 47.3216 2.7 3.4 0.18 Im T2 43.797 3.5 4.4 0.15 C1 Primary (RUL) 103.7125 1.7 3.0 0.14 C1 T2 49.9054 2.78 4.78 0.21 C1 L Liver 71.7364 5 8.6 0.42 C2* Primary (RUL) 97.159 0.11 C2* T2 81.58 0.13 C2* L Liver 82.346 0.24 1Partial Volume Correction applied 2Lesions were contours based on thresholding (40%) method and volume was averaged over all timepoints. 3Density of lesion: soft tissue = 1.0 g/mL. Bone = 1.3 g/mL *BR = background – shoulder and proximal thigh. T:BR = lesion SUVmax:BR SUVmean 25 IMD2 IMD2 SUV 6 5 4 3 2 1 0 7 ImD – T2 ImD – Primary (RUL) IMD3 IMD3 IMD4 IMD4 Location of sampling PD-L1 expression IHC (%) Right lung 30 x Cohort 1 - 30mCi Dose Level Preliminary Clinical Activity (PFS of 5+ months) in 2/3 subjects (67%) exceeds historical controls 26 RAD 204 THERAPEUTIC 1subjects without actionable mutations. Soon YY, et al. Clinical Trial and Real-World Outcomes of subjects With Metastatic NSCLC in the Post-Platinum-Based Chemotherapy Failure Setting. JTO Clin Res Rep. 2023;4(11):100579. Published 2023 Sep 28. doi:10.1016/j.jtocrr.2023.100579. 0 1 2 3 4 5 6 Participant Dose RAD204 – Swimmer Lane Plot 003-006_(DL1/30mCi/1.1GBq) 003-002_(DL1/30mCi/1.1GBq) 003-001_(DL1/30mCi/1.1GBq) NSCLC Last Line Historical Progression Free Survival ≅ 3.5 months1 Event Type Stable disease (SD) Disease Progression 177Lu-RAD204 Dose administered Months from Cycle 1 Lesion Dosimetry | Second Cohort at 60 mCi Data from a single administration in all three patients. RAD 204 THERAPEUTIC PATIENT #1 PATIENT #4 Absorbe d dose at 60 mCi Cycle Lesion Volume (ml)2 D1 SUVmax SUV T:BR* Dose (Gy), with PVC1,2 C1 Primary 113 2.1 5.1 0.33 C1 Lymph node axillary left (ROI-3) 27 2.7 6.6 0.61 C1 Lymph node supraclavicular left (ROI-4) 27 3 7.3 0.7 C1 Lymph node supraclavicular right (Level V) (ROI-6) 37 1.8 4.3 0.35 C1 Liver Segment VI (ROI-9) 47 6.3 15.4 3.0 # Patient 003-009 is not DLT-evaluable (consent withdrawal due to personal reasons) 1Partial Volume Correction applied. 2Density of lesion: soft tissue = 1.0 g/mL. Bone = 1.3 g/mL 3Lesions were contours based on thresholding (40%) method and volume was averaged over all timepoints *BR = background – shoulder and proximal thigh. T:BR = lesion SUVmax:BR SUVmean 27 Absorbed dose at 60 mCi Cycl e Lesion Volume (ml)2 D1 SUVmax SUV T:BR* Dose (Gy), with PVC1,2 C1 ROI-4 8.3 2.5 4.7 0.5 Absorbed dose at 60 mCi Cycle Lesion Volume (ml)2 D1 SUVmax SUV T:BR* Dose (Gy) IM with PVC1,2 Dose (Gy) C1 with PVC1,2 IM ROI-7 (Spleen) 16.28 15.2 20.7 1.0 2.8 PATIENT #5 PATIENT #6 Treatment-Emergent and Treatment-Related Adverse Events • Majority of TEAEs in Dose Levels 1 and 2 were CTC Grade 1 and 2 • There were a total of four Grade 3 events, all of which were pre-existing at study entry • Only one of the Grade 3 events was considered ‘related’ by the treating physician, despite it being pre-existing at study entry: increased lipase (isolated, asymptomatic) Serious Adverse Events • There were n=2 SAEs in Dose Levels 1 and 2. None were related to study drug • N=2 subjects experienced SAEs (resulting in hospitalization) which were due to 1) subject with worsening of previous underlying non-cancerous condition (lung infection) and 2) n=1 subject with worsening of underlying cancerous condition (progression of disease) • Neither of these two subjects received a therapeutic dose of the study drug. One subject only underwent screening, the other subject only received one imaging dose of 10mCi Adverse Events Summary (interim data) | Dose Levels 1 and 2 RAD 204 THERAPEUTIC Molecule: 68Ga-RAD301 Targeting MoA: αVβ6 INTEGRIN Imaging for: PANCREATIC CANCER 29 RAD 301 (Trivehexin) PEPTIDE • RGD peptide (arginylglycylaspartic acid) • Integrin αvβ6 receptor antagonist • Design features include hydrophilicity to reduce non-specific uptake into undesired organs and increase clearance in plasma, trimerization to increase affinity, cyclicity for better selectivity, uptake and tumor retention Imaging for Pancreatic Cancer 68Ga, gallium-68; αvβ6, alpha-v beta-6; ADC, antibody drug conjugate; IIa, phase 2a; n, number of subjects; NSCLC, non-small cell lung cancer; RGD, arginylglycylaspartic acid; TGFβ, transforming growth factor beta; Tx, treatment. 30 CANCER CELL TARGET integrin αvβ6 TARGETING MOLECULE trivehexin LINKER RADIOACTIVE ISOTOPE 68Ga INTEGRIN αvβ6 ✚ Upregulated target often referred to as “cancer integrin” given its role in activation of TGFβ; expression correlates with decreased survival in numerous carcinomas. ✚ Pfizer αvβ6 integrin ADC Phase III in NSCLC. αvβ6 INTEGRIN EXPRESSING TUMORS ✚ Pancreatic cancer is first targeted indication (~60% expression). ✚ Approx. n=80 subjects already dosed in IIS and under German compassionate use program. ✚ Strong peer reviewed presence in several journals and congresses. RAD 301 DIAGNOSTIC • 44 subjects: Pancreatic Ductal Adenocarcinoma (PDAC) imaged under 3rd party (Germany) compassionate use* • 32 subjects: 12 PDAC, 20 Head & Neck Squamous Cell Carcinoma(HNSCC) imaged in Investigator Initiated Research (IIR)** • 4 subjects: single case publications in Non-Small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Ovarian, Thyroid Cancer • Ongoing Phase 1 imaging study in Pancreatic Cancer ongoing at Montefiore, NY and United Theranostic, NJ*** • Phase 1 is used to confirm Proof-Of Concept in subjects with metastatic pancreatic cancer • Phase 2 in preparation in subjects with loco-regional disease (pre-metastatic) 80 Subjects Imaged With 68GA-RAD301 To Date Multi-indication Potential Beyond Pancreatic Cancer 3rd PARTY COMPASSIONATE USE (Germany)* IIR IN PDAC & HNSCC** + 4 Single Case Publications PHASE 1 (USA)*** Phase 2 (USA) 44 pts 32 pts + 4 pts = 36 pts 9 pts 30 pts Ongoing In Preparation *Rehm J, et al. Front. Nucl. Med. 4:1487602. doi: 10.3389/fnume.2024.1487602, **Das, S. et al,. Clin Nucl Med 49, 733–740. doi.org/10.1097/RLU.0000000000005278 *** NCT05799274. HNSCC, head and neck squamous cell carcinoma; IIR, investigator-initiated research; NSCLC, non-small cell lung cancer; PDAC, pancreatic ductal adenocarcinoma; TNBC, triple negative breast cancer. 31 RAD 301 DIAGNOSTIC UPCOMING MILESTONES PROGRAM 2NDHALF 2024 1ST HALF 2025 2NDHALF 2025 RAD301 Phase I Phase 1 ongoing Phase 1 ongoing Last patient dosed ACHIEVED PROGRAM 1ST HALF 2026 2NDHALF 2026 1ST HALF 2027 2ND HALF 2027 RAD301 Phase 2 CLINICAL SITES EXPANSION TRIAL START ENROLLING TRIAL COMPLETED TRIAL POPULATION Metastatic Pancreatic Cancer - Adequate for proof of concept - subjects with more extensive disease, more frail, difficult to recruit - Limited patient benefit TRIAL POPULATION Loco-Regional Pancreatic Cancer High risk of metastatic disease - Higher unmet need - Higher patient benefit - Healthier patient population - Easier to recruit - More willing to participate in trials - Larger prevalence 32 Executive Summary 33 RAD 301 DIAGNOSTIC αVβ6, alpha-v beta-6 integrin; cm, centimeter; GYN, gynecologic; n, number of subjects; RAD301, radiolabeled αVβ6-targeted diagnostic agent. • Phase 1 company-sponsored study underway in healthy volunteers and pancreatic cancer subjects to characterize biodistribution, image quality and organ/tumor dosimetry • Preliminary results from n=3 subjects in RADs ongoing study thus far suggest high sensitivity for detection and monitoring of primary tumors and metastatic lesions as small as <1cm • 6 subjects dosed as 10/20/2025; expected 9/9 subjects by Dec 2025 PET/CT Scan | Patient 1 Pancreatic Cancer patient with large pancreatic mass visible in PET RAD 301 DIAGNOSTIC Axial Slice 289/423 Coronal Slice 82/144 AC, attenuation corrected; PET, positron emission tomography. 34 PET/CT Scan | Patient 2 Pancreatic Cancer patient with multiple bilateral metastatic pulmonary nodules ranging in size from 1.3 to 2.2. cm RAD 301 DIAGNOSTIC Axial cm, centimeter; CT, computed tomography; PET, positron emission tomography. 35 PET/CT Scan | Patient 3 Pancreatic cancer patient with multiple metastatic lung nodules <1cm RAD 301 DIAGNOSTIC Axial cm, centimeter; CT, computed tomography; PET, positron emission tomography. 36 Appendix www.radiopharmtheranostics.com 37 RAD is at the Cutting Edge of Radiopharmaceuticals, a Transformative Modality Within Cancer TREATMENT Radiopharmaceuticals Expertise, In licensing Strategy & Intellectual Property • All team members with previous imaging and therapeutic radiopharmaceutical experience • Scientific Advisory Board of accredited multinational researchers • Extensive patent portfolio for targets through 2040 Differentiated Within Radiopharmaceuticals • Clinical-stage company with deep pipeline of radiotherapeutic assets pursuing novel targets – Targets include PD-L1, HER2 (nanobody platform); integrin αVβ6 (peptide) fatty acid synthase (small molecule) – Six trials anticipated to be in clinical stage by December 2025; 2 Diagnostics (Brain Mets; Pancreas) and 4 Therapeutics (PD-L1; HER2; B7H3, KLK3) – Radiopharm Ventures, a Joint Venture with MD Anderson Cancer Center - in-licensed from MDACC technologies for radiopharmaceuticals use. First technology has been disclosed (B7H3- targeting molecule) Fully funded to achieve multiple near-term catalysts with the potential for value creation • Q4 2025 (ongoing): Interim data released for Phase 2b imaging study of RAD-101 (Brain Mets) – Positive data from first 3 patients now available (see pages 9 – 11) ​ • Q4 2025 (ongoing): Interim data released from Phase 1 study with RAD301 (AvB6) – Positive data from first 3 patients now available (see pages 33 – 35)​ • Q4 2025 (ongoing): Early cohort data from Phas